1. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-113618A
    RO2959 hydrochloride 1219927-22-6 98%
    RO2959 hydrochloride is a potent and selective CRAC channel inhibitor with an IC50 of 402 nM. RO2959 hydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC50 of 25 nM. RO2959 hydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways.
    RO2959 hydrochloride
  • HY-114161A
    H-Val-Pro-Pro-OH TFA 2828433-08-3 ≥98.0%
    H-Val-Pro-Pro-OH (TFA), a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC50 of 9 μM.
    H-Val-Pro-Pro-OH TFA
  • HY-114293A
    Acetyl coenzyme A trilithium 75520-41-1
    Acetyl-coenzyme A (Acetyl-CoA) trilithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trilithium regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trilithium is also a key precursor of lipid synthesis.
    Acetyl coenzyme A trilithium
  • HY-114424A
    H-Ile-Pro-Pro-OH hydrochloride 1208862-61-6 98.48%
    H-Ile-Pro-Pro-OH hydrochloride, a milk-derived peptide, inhibits angiotensin-converting enzyme (ACE) with an IC50 of 5 μM. Antihypertensive tripeptides.
    H-Ile-Pro-Pro-OH hydrochloride
  • HY-116678A
    Cloricromen hydrochloride 74697-28-2 99.82%
    Cloricromen (Cloricromene) hydrochloride is a platelet aggregation inhibitor. Cloricromen hydrochloride can inhibit platelet aggregation in man and in experimental thrombosis.
    Cloricromen hydrochloride
  • HY-119541A
    Ampreloxetine TFA 1227056-85-0 98.30%
    Ampreloxetine (TD-9855) TFA is a potent and orally active norepinephrine (NE) and serotonin 5-HT inhibitor. Ampreloxetine TFA has the potential for the research of neurogenic orthostatic hypotension.
    Ampreloxetine TFA
  • HY-121538A
    CUDA disodium 98.0%
    CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease.
    CUDA disodium
  • HY-125053A
    Batifiban TFA 99.58%
    Batifiban TFA, a cyclic peptide, is an antagonist of platelet glycoprotein GPⅡb/Ⅲa and inhibits platelet aggregation. Batifiban blocks the binding of circulating vitronectin to integrin ανβ3.
    Batifiban TFA
  • HY-128090A
    Apstatin TFA 99.43%
    Apstatin TFA is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin TFA shows cardioprotection.
    Apstatin TFA
  • HY-137683A
    Guanosine 5'-O-(2-thiodiphosphate) trisodium
    Guanosine 5'-O-(2-thiodiphosphate) (trisodium) (GDPβS (trisodium)) is a non-hydrolyzable derivative of GDP. Guanosine 5'-O-(2-thiodiphosphate) (trisodium) is an inhibitor of adenylyl caclase (AC) (Ki = 600 nM). Guanosine 5'-O-(2-thiodiphosphate) (trisodium) partially activates AC in the absence of GPT in cerebral cortex membranes of rodent models (EC50 = 400 nM). Guanosine 5'-O-(2-thiodiphosphate) (trisodium) prevents the release of norepinephrine-induced nitric oxide in cardiac ventricular myocytes.
    Guanosine 5'-O-(2-thiodiphosphate) trisodium
  • HY-158024A
    (S)-NDT-19795 98%
    (S)-NDT-19795 is a potent NLRP3 inflammasome inhibitor. (S)-NDT-19795 blocks NLRP3 activation by inhibiting NLRP3 ATPase activity, thereby reducing the levels of pro-inflammatory cytokines IL-1β and IL-18. (S)-NDT-19795 can be used in the study of neurodegenerative diseases, cardiovascular diseases, metabolic diseases, and autoimmune diseases.
    (S)-NDT-19795
  • HY-17376S1
    Ezetimibe-d4-1 1093659-89-2 99.26%
    Ezetimibe-d4-1 is deuterium labeled Ezetimibe. Ezetimibe (SCH 58235) is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
    Ezetimibe-d4-1
  • HY-18204S2
    Valsartan-d8 1089736-72-0 99.90%
    Valsartan-d8 is the deuterium labeled Valsartan. Valsartan (CGP 48933) is an angiotensin II receptor antagonist and has the potential for high blood pressure and heart failure research.
    Valsartan-d8
  • HY-B0205S1
    Candesartan-d5 1189650-58-5
    Candesartan-d5 is the deuterium labeled Candesartan. Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.
    Candesartan-d5
  • HY-B0252S1
    Hydrochlorothiazid-13C,d2 1190006-03-1 98.64%
    Hydrochlorothiazid-13C,d2 is the 13C- and deuterium labeled Hydrochlorothiazide. Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect.
    Hydrochlorothiazid-13C,d2
  • HY-B0715S2
    Pentoxifylline-d5 1185995-18-9 99.89%
    Pentoxifylline-d5 is the deuterium labeled Pentoxifylline. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation.
    Pentoxifylline-d5
  • HY-N0470S4
    L-Lysine-d8 hydrochloride 344298-93-7 99.88%
    L-Lysine-d8 (hydrochloride) is the deuterium labeled L-Lysine hydrochloride. L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health.
    L-Lysine-d8 hydrochloride
  • HY-P10948A
    CS-VIP 8 hydrochloride
    CS-VIP 8 hydrochloride is a selective allosteric WDR5 protein inhibitor (Ki= 0.008 μM). CS-VIP 8 hydrochloride induces conformational changes in the MLL1 complex, leading to the dissociation of MLL1 from the complex, inhibiting MLL1 histone methyltransferase activity and regulating HOX gene expression. CS-VIP 8 hydrochloride is promising for research of hematological diseases such as leukemia.
    CS-VIP 8 hydrochloride
  • HY-P991065
    Ichorcumab 2589583-20-8
    Ichorcumab (JNJ-375) is a fully human IgG4 antibody that targets Thrombin. Ichorcumab binds to exosite 1 on thrombin and inhibits substrate binding but not catalytic activity. The isotype control for Ichorcumab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).
    Ichorcumab
  • HY-W013989
    1,3-Dicyclohexylurea 2387-23-7
    1,3-Dicyclohexylurea (DCU) is an orally active and potent sEH (soluble epoxide hydrolase) inhibitor. Oral Delivery of 1,3-Dicyclohexylurea nanosuspension enhances exposure and lowers blood pressure in hypertensive Rats.
    1,3-Dicyclohexylurea
Cat. No. Product Name / Synonyms Application Reactivity